ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 2 filers reported holding ARGENX SE in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,671 | -16.5% | 5,339 | -14.1% | 0.06% | -11.6% |
| Q2 2023 | $3,200 | +43.0% | 6,213 | +3.5% | 0.07% | +30.2% |
| Q1 2023 | $2,237 | +9.3% | 6,004 | +11.1% | 0.05% | +3.9% |
| Q4 2022 | $2,046 | -99.9% | 5,403 | -2.6% | 0.05% | -5.6% |
| Q3 2022 | $1,958,000 | -9.7% | 5,545 | -3.1% | 0.05% | -3.6% |
| Q2 2022 | $2,168,000 | +22.6% | 5,722 | +2.1% | 0.06% | +43.6% |
| Q1 2022 | $1,768,000 | -0.5% | 5,607 | +10.5% | 0.04% | 0.0% |
| Q4 2021 | $1,777,000 | +3.9% | 5,074 | -10.4% | 0.04% | -2.5% |
| Q3 2021 | $1,711,000 | +8.0% | 5,665 | +7.7% | 0.04% | +8.1% |
| Q2 2021 | $1,584,000 | +5.7% | 5,260 | -3.3% | 0.04% | 0.0% |
| Q1 2021 | $1,499,000 | -10.0% | 5,442 | -3.9% | 0.04% | -11.9% |
| Q4 2020 | $1,665,000 | +15.7% | 5,662 | +3.3% | 0.04% | +5.0% |
| Q3 2020 | $1,439,000 | +12.6% | 5,483 | -3.4% | 0.04% | +8.1% |
| Q2 2020 | $1,278,000 | – | 5,675 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 273,343 | $106,529,967 | 17.42% |
| Kynam Capital Management, LP | 184,300 | $71,827,239 | 9.88% |
| Ikarian Capital, LLC | 132,100 | $51,483,333 | 8.20% |
| Avoro Capital Advisors LLC | 1,263,500 | $492,423,855 | 6.68% |
| Artia Global Partners LP | 46,438 | $18,098,282 | 6.24% |
| DCF Advisers, LLC | 25,700 | $10,016,061 | 5.29% |
| Bellevue Group AG | 923,284 | $359,831,473 | 5.13% |
| Eagle Health Investments LP | 64,400 | $25,098,612 | 4.69% |
| Paradigm Biocapital Advisors LP | 150,000 | $58,459,500 | 4.52% |
| Paradigm Biocapital Advisors LP | 142,259 | $55,442,600 | 4.28% |